Survival analysis of NSCLC patients with exon 18, 19, 20, and 21 mutations showed that the progression-free survival of NSCLC patients with exon 18, 19, 20, and 21 mutations was significantly lower than that of patients with wild-type EGFR (Figure 3E), but the overall survival of NSCLC patients with exon 18, 19, 20, and 21 mutations was, within 50 months of survival, significantly higher than the wild-type (Figure 3F). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.